CoChat

Comprehensive Predictive Biomarker Analysis for MEK Inhibitor GSK1120212

Jing, Junping, Greshock, Joel, Holbrook, Joanna Dawn, Gilmartin, Aidan, Zhang, Xiping, McNeil, Elizabeth, Conway, Theresa, Moy, Christopher, Laquerre, Sylvie, Bachman, Kurt, Wooster, Richard, Degenhardt, Yan · 2012 · Molecular Cancer Therapeutics

Published version of a preprint

Cited by 121

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

The MEK1 and MEK2 inhibitor GSK1120212 is currently in phase II/III clinical development. To identify predictive biomarkers, sensitivity to GSK1120212 was profiled for 218 solid tumor cell lines and 81 hematologic malignancy cell lines. For solid tumors, RAF/RAS mutation was a strong predictor of sensitivity. Among RAF/RAS mutant lines, co-occurring PIK3CA/PTEN mutations conferred a cytostatic response instead of a cytotoxic response for colon cancer cells that have the biggest representation of the comutations. Among KRAS mutant cell lines, transcriptomics analysis showed that cell lines with an expression pattern suggestive of epithelial-to-mesenchymal transition were less sensitive to GSK1120212. In addition, a proportion of cell lines from certain tissue types not known to carry frequent RAF/RAS mutations also seemed to be sensitive to GSK1120212. Among these were breast cancer cell lines, with triple negative breast cancer cell lines being more sensitive than cell lines from other breast cancer subtypes. We identified a single gene DUSP6, whose expression was associated with sensitivity to GSK1120212 and lack of expression associated with resistance irrelevant of RAF/RAS status. Among hematologic cell lines, acute myeloid leukemia and chronic myeloid leukemia cell lines were particularly sensitive. Overall, this comprehensive predictive biomarker analysis identified additional efficacy biomarkers for GSK1120212 in RAF/RAS mutant solid tumors and expanded the indication for GSK1120212 to patients who could benefit from this therapy despite the RAF/RAS wild-type status of their tumors. Mol Cancer Ther; 11(3); 720–9. ©2011 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1535-7163.mct-11-0505

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Research works printed but not linked: 32

  1. Montagut, 2009, Targeting the RAF-MEK-ERK pathway in cancer therapy, Cancer Lett, 283, 125, 10.1016/j.canlet.2009.01.022 · DOI · Paper page
  2. Moasser, 2007, Targeting the function of the HER2 oncogene in human cancer therapeutics, Oncogene, 26, 6577, 10.1038/sj.onc.1210478 · DOI · Paper page
  3. Takeuchi, 2010, EGF receptor in relation to tumor development: molecular basis of responsiveness of cancer cells to EGFR-targeting tyrosine kinase inhibitors, FEBS J, 277, 316, 10.1111/j.1742-4658.2009.07450.x · DOI
  4. Yap, 2010, Targeting the HGF/c-Met axis: state of play, Mol Cancer Ther, 9, 1077, 10.1158/1535-7163.MCT-10-0122 · DOI
  5. Weinstein, 2002, Cancer. Addiction to oncogenes–the Achilles heal of cancer, Science, 297, 63, 10.1126/science.1073096 · DOI · Paper page
  6. Druker, 2001, Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia, N Engl J Med, 344, 1031, 10.1056/NEJM200104053441401 · DOI · Paper page
  7. Rusnak, 2007, Assessment of epidermal growth factor receptor (EGFR, ErbB1) and HER2 (ErbB2) protein expression levels and response to lapatinib (Tykerb, GW572016) in an expanded panel of human normal and tumour cell lines, Cell Prolif, 40, 580, 10.1111/j.1365-2184.2007.00455.x · DOI · Paper page
  8. Spector, 2005, Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies, J Clin Oncol, 23, 2502, 10.1200/JCO.2005.12.157 · DOI · Paper page
  9. Garon, 2010, Identification of common predictive markers of in vitro response to the Mek inhibitor selumetinib (AZD6244; ARRY-142886) in human breast cancer and non-small cell lung cancer cell lines, Mol Cancer Ther, 9, 1985, 10.1158/1535-7163.MCT-10-0037 · DOI · Paper page
  10. Solit, 2006, BRAF mutation predicts sensitivity to MEK inhibition, Nature, 439, 358, 10.1038/nature04304 · DOI · Paper page
  11. Rinehart, 2004, Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer, J Clin Oncol, 22, 4456, 10.1200/JCO.2004.01.185 · DOI · Paper page
  12. Sznol, 2011, Molecular markers of response to treatment for melanoma, Cancer J, 17, 127, 10.1097/PPO.0b013e318212dd5a · DOI
  13. Gilmartin, 2011, GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition, Clin Cancer Res, 17, 989, 10.1158/1078-0432.CCR-10-2200 · DOI · Paper page
  14. Greshock, Molecular target class is predictive of in vitro response profile, Cancer Res, 70, 3677, 10.1158/0008-5472.CAN-09-3788 · DOI · Paper page
  15. Charafe-Jauffret, 2006, Gene expression profiling of breast cell lines identifies potential new basal markers, Oncogene, 25, 2273, 10.1038/sj.onc.1209254 · DOI · Paper page
  16. Voskoglou-Nomikos, 2003, Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models, Clin Cancer Res, 9, 4227
  17. Brachmann, 2009, PI3K and mTOR inhibitors: a new generation of targeted anticancer agents, Curr Opin Cell Biol, 21, 194, 10.1016/j.ceb.2008.12.011 · DOI
  18. Sabbah, 2008, Molecular signature and therapeutic perspective of the epithelial-to-mesenchymal transitions in epithelial cancers, Drug Resist Updat, 11, 123, 10.1016/j.drup.2008.07.001 · DOI · Paper page
  19. Singh, 2009, A gene expression signature associated with “K-Ras addiction” reveals regulators of EMT and tumor cell survival, Cancer Cell, 15, 489, 10.1016/j.ccr.2009.03.022 · DOI · Paper page
  20. Badve, 2011, Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists, Mod Pathol, 24, 157, 10.1038/modpathol.2010.200 · DOI · Paper page
  21. Tentler, 2010, Identification of predictive markers of response to the MEK1/2 inhibitor selumetinib (AZD6244) in K-ras-mutated colorectal cancer, Mol Cancer Ther, 9, 3351, 10.1158/1535-7163.MCT-10-0376 · DOI · Paper page
  22. Furukawa, 2008, Feedback regulation of DUSP6 transcription responding to MAPK1 via ETS2 in human cells, Biochem Biophys Res Commun, 377, 317, 10.1016/j.bbrc.2008.10.003 · DOI
  23. Sharma, 2006, A common signaling cascade may underlie “addiction” to the Src, BCR-ABL, and EGF receptor oncogenes, Cancer Cell, 10, 425, 10.1016/j.ccr.2006.09.014 · DOI · Paper page
  24. Takahashi, 2006, Inhibition of the MEK/MAPK signal transduction pathway strongly impairs the growth of Flt3-ITD cells, Am J Hematol, 81, 154, 10.1002/ajh.20520 · doi:10.1002/ajh.20520
  25. Brufsky, 2010, Trastuzumab-based therapy for patients with HER2-positive breast cancer: from early scientific development to foundation of care, Am J Clin Oncol, 33, 186, 10.1097/COC.0b013e318191bfb0 · DOI
  26. Parsons, 2005, Colorectal cancer: mutations in a signalling pathway, Nature, 436, 792, 10.1038/436792a · DOI · Paper page
  27. Velho, 2005, The prevalence of PIK3CA mutations in gastric and colon cancer, Eur J Cancer, 41, 1649, 10.1016/j.ejca.2005.04.022 · DOI · Paper page
  28. Halilovic, 2008, Therapeutic strategies for inhibiting oncogenic BRAF signaling, Curr Opin Pharmacol, 8, 419, 10.1016/j.coph.2008.06.014 · DOI
  29. Shin, 2010, Functional roles of multiple feedback loops in extracellular signal-regulated kinase and Wnt signaling pathways that regulate epithelial-mesenchymal transition, Cancer Res, 70, 6715, 10.1158/0008-5472.CAN-10-1377 · DOI · Paper page
  30. Uramoto, 2011, Expression of selected gene for acquired drug resistance to EGFR-TKI in lung adenocarcinoma, Lung Cancer, 73, 361, 10.1016/j.lungcan.2011.01.008 · DOI
  31. Siziopikou, 2007, The basal subtype of breast carcinomas may represent the group of breast tumors that could benefit from EGFR-targeted therapies, Breast, 16, 104, 10.1016/j.breast.2006.09.003 · DOI
  32. Pratilas, 2009, (V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway, Proc Natl Acad Sci U S A, 106, 4519, 10.1073/pnas.0900780106 · DOI · Paper page

Cited by

See all 121

Metadata

Authors
Jing, J., Greshock, J., Holbrook, J. D., Gilmartin, A., Zhang, X., McNeil, E., Conway, T., Moy, C., Laquerre, S., Bachman, K., Wooster, R., & Degenhardt, Y.
Venue
Molecular Cancer Therapeutics
Published
2012-03-01
Volume
11
Issue
3
Pages
720-729
ISSN
  • 1535-7163 (ISSN-L)
  • 1538-8514
OpenAlex
W2125316253
Cited by
121
References
4
FWCI
3.88
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Comprehensive Predictive Biomarker Analysis for MEK Inhibitor GSK1120212. https://app.cochat.ai/papers/10.1158/1535-7163.mct-11-0505
The paper
Jing, J., Greshock, J., Holbrook, J. D., Gilmartin, A., Zhang, X., McNeil, E., Conway, T., Moy, C., Laquerre, S., Bachman, K., Wooster, R., & Degenhardt, Y. (2012). Comprehensive Predictive Biomarker Analysis for MEK Inhibitor GSK1120212. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-11-0505

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.